We. Pullman et Wf. Doe, IL-2 PRODUCTION BY INTESTINAL LAMINA PROPRIA CELLS IN NORMAL INFLAMEDAND CANCER-BEARING COLONS, Clinical and experimental immunology, 88(1), 1992, pp. 132-137
Biologically significant levels of IL-2 activity were produced by isol
ated lamina propria mononuclear cells (LPMC) from normal intestine (n
= 12), cancer-bearing colons (n = 35) and inflammatory bowel disease (
IBD) affected tissue (n = 12). The levels of IL-2 produced were simila
r for all three sources of LPMC (normal 252 +/- 48 U/ml, IBD-affected
mucosa 197 +/- 42 U/ml and colon cancer 285 +/- 43 U/ml). These levels
were significantly greater than those produced by peripheral blood mo
nonuclear cells (20 +/- 5 U/ml, P < 0.01) on a per cell basis. In muco
sa from cancer-bearing colons the amount of IL-2 produced by LPMC was
unaffected by the invasiveness of the colon cancer. LPMC IL-2 producti
on was markedly suppressed by drugs used in IBD therapy. 5-Aminosalicy
clic acid (5-ASA) reduced activity in a dose-dependent fashion. At a d
ose equivalent to the faecal therapeutic level of 0.5 mg/ml activity,
IL-2 production by LPMC was suppressed to 3.4% of controls. Similarly,
exposure of LPMC to cyclosporin A (CyA) and hydrocortisone (HC) at th
erapeutic levels reduced IL-2 activity to less than 1% of controls. Th
e major producers of IL-2 activity were shown to be CD3+ T lymphocytes
and those bearing the activation markers IL-2R and TFR. Suppression o
f mucosal IL-2 production represents an important therapeutic mechanis
m of drugs used in the management of IBD including HC, 5-ASA and CyA.
These results suggest that mucosal T cells produce appreciable levels
of IL-2 activity that may be important in maintaining immune homeostas
is in the normal intestine, provide anti-neoplastic cytotoxic activity
and contribute to the inflammatory events that characterize the mucos
al lesions of IBD.